Climb Bio Reports Third Quarter 2024 Financial Results and Business Highlights

Appointed Douglas Williams, Ph.D. as Chair of the Board of Directors FDA Clearance of Investigational New Drug Application (IND) for systemic lupus erythematosus (SLE) Expanded Management Team with the Appointment of Gary Hao, Ph.D. as Vice President of Chemistry, Manufacturing and Controls Highlights Timing of Key Upcoming Milestones Cash Runway Remains through 2027 Expected to Enable Delivery of Key Value Inflection Points WELLESLEY HILLS, Mass., Nov. 12, 2024 (GLOBE NEWSWIRE) -- Climb Bio, Inc. (Nasdaq: ...